Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study

BACKGROUND: Programmed cell death 1 (PD-1) inhibitors are beneficial for patients with advanced lung cancer. However, the population who will benefit from PD-1 inhibitors is limited, and their efficacy needs to be further improved. Antiangiogenic agents may regulate tumor microenvironment to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xuanting, Huang, Aimi, Zhou, Yan, Kuang, Yanbin, Wang, Weimin, Gu, Aiqin, Xu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183545/
https://www.ncbi.nlm.nih.gov/pubmed/37197506
http://dx.doi.org/10.21037/jtd-23-289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183545/
https://www.ncbi.nlm.nih.gov/pubmed/37197506
http://dx.doi.org/10.21037/jtd-23-289

Ejemplares similares